Dabigatran dose testing needed: BMJ

All patients starting dabigatran should undergo initial drug-level monitoring and dose adjustment due to a wide variation in plasma levels of the drug, a BMJ analysis suggests.

An in-depth investigation by the journal published Thursday reports on new evidence of a fivefold variation in dabigatran (Pradaxa) levels that it says may put some patients with atrial fibrillation at risk of serious bleeding, and leave others undertreated for stroke risk.

The journal